knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 17:01:58 - browse：91

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Target recalls 2.2 million additional candles due to laceration, burn hazards

leisure time

WSS

Listen: Your guide to Wegovy's blockbuster heart study

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Large hospital system sues Multiplan for low

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

focus

knowledge

hotspot

Continuity nursing helped my family in our darkest PICU moments

Large hospital system sues Multiplan for low

Apple is now the first public company to be valued at $3 trillion

CDC overhauls leadership of center that led response to Covid

Guidelines to prevent youth baseball injuries need more muscle

Pharma budget tightening trickles down to Doximity

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

After John Oliver segment, STAT readers share their opioid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

focus

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

GOP presidential candidates start declaring their loyalty

GOP presidential candidates start declaring their loyalty

After John Oliver segment, STAT readers share their opioid

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Listen: Your guide to Wegovy's blockbuster heart study

Wikipedia

leisure time

focus

explore